The event will take place from 27 November to 2 December in Illinois.
Earlier this month, Arterys Software platform secured 510(k) clearance from the US Food and Drug Administration (FDA) for use in clinical settings for the quantification of cardiac flow that includes 4D Flow and 2D Phase Contrast workflows, and cardiac function measurements.
The 4D Flow technique enables physicians to measure and visualize blood patterns within the acquired 3D volume.
It provides faster scans and simplified processes compared against conventional MRI that requires multiple scans while the patient holds their breath.
Through collaborating with GE Healthcare, the company plans to launch the new software in the US as the ViosWorks 4D product.
Featuring Arterys software, ViosWorks is the cardiovascular solution that involves in cloud-based and real-time processing of images with resolutions previously unattainable.
The company will also reveal new data on cardiac clinical applications using the Arterys 4D Flow software during the RSNA poster sessions
Arterys CEO Fabien Beckers said: "This year, RSNA is focusing a lot of attention on breakthrough technological developments that are moving medical imaging into a new era where it's possible to analyze data to help diagnose conditions much quicker, align various stakeholders in the health ecosystem, and mobilize on personalized treatment paths.
“We believe the Arterys platform will transform clinical practice through powerful, quantitative imaging tools that rapidly generate and analyze unprecedented amounts of data and insights that can support treatment decisions and the delivery of patient care."
Image: Arterys Software platform secured FDA approval for use in clinical settings for the quantification of cardiac flow. Photo: courtesy of PRNewsFoto/Arterys.
